Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival-Reference-Cited by-同舟云学术

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

Published:2018-06-15 Issue:2 Volume:54 Page:293-299
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Hari Parameswaran,Reece Donna E.,Randhawa Jasleen,Flomenberg Neal,Howard Dianna S.,Badros Ashrof Z.,Rapoport Aaron P.,Meisenberg Barry R.,Filicko-Ohara Joanne,Phillips Gordon L.,Vesole David H.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0261-y.pdf

Reference35 articles.

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83. https://doi.org/10.1056/NEJMoa02234 .

2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–7. https://doi.org/10.1056/NEJM199607113350204 .

3. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. https://doi.org/10.1056/NEJMoa1611750

4. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–29. https://doi.org/10.1016/S1470-2045(15)00389-7

5. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905. https://doi.org/10.1056/NEJMoa1402888

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulatory effect of amifostine (WR-1065) against genotoxicity and oxidative stress induced by methotrexate in human umbilical vein endothelial cells (HUVECs);Toxicology Mechanisms and Methods;2023-08-03

2. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

3. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m² versus 200mg/m² preparative regimens in patients with multiple myeloma;Leukemia & Lymphoma;2023-05-18

4. Stem Cell Transplant for Plasma Cell Dyscrasias;Basics of Hematopoietic Stem Cell Transplant;2023

5. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma;Transplantation and Cellular Therapy;2022-09